How a two-month brainstorming session led to FDA reform proposals reaching the President's desk. Jake Becraft, CEO of Strand Therapeutics, discusses building the future of genetic medicine through platform-based drug delivery, regulatory innovation, and capital formation strategies that mirror SpaceX's approach to solving the 30-year bottleneck of getting RNA medicines beyond the liver to treat previously intractable diseases. Genetic medicine's 30-year bottleneck has trapped IV treatments in the liver; Strand demonstrated abscopal response in visceral organ metastases, showing tumors can activate immune systems to target distant cancers without direct injection.